Clinical Trial Update: Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports results for pembrolizumab in relapsed or refractory multiple myeloma after anti-BCMA CAR-T therapy; the study is terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Alfred Chung, MD | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Status: TERMINATED | Results posted: 2025-01-15